Home > Education & Research > Research to Improve Health Care > Participating in Research > Clinical Trials > Clinical Trials Details
<< Back to Results
This randomized phase III trial studies enzalutamide to see how well it works compared to enzalutamide, abiraterone, and prednisone in treating patients with castration-resistant metastatic prostate cancer. Androgens can cause the growth of prostate cancer cells. Drugs, such as enzalutamide, abiraterone acetate, and prednisone, may lessen the amount of androgens made by the body.
https://www.clinicaltrials.gov/ct2/show/NCT01949337
Location:
Essentia Health Duluth
Disclosures:
None
For more information about a financial conflict of interest (FCOI), review the Essentia Health FCOI policy.
